[20211122]IF11951_2019冠状病毒疾病疫苗的国内资金：概述 .pdf

https:/crsreports.congress.gov Updated November 22, 2021Domestic Funding for COVID-19 Vaccines: An Overview Federal efforts to develop, manufacture, purchase, and distribute Coronavirus Disease 2019 (COVID-19) vaccines have involved a number of agencies. Many of these efforts have thus far been funded by appropriations in COVID-19 relief acts, especially funding to the Department of Health and Human Services (HHS) U.S. Public Health Service (PHS) agencies and accounts in FY2020 and FY2021 supplemental appropriations and in the American Rescue Plan Act (ARPA, P.L. 117-2) budget reconciliation measure enacted in March 2021. The following provides an overview of both (1) appropriations and (2) allocations and obligations for selected domestic COVID-19 vaccine related activities. (With the exception of the mandatory funding provided by ARPA, all funding amounts discussed below are classified as discretionary.) The following is meant to inform a general understanding of relevant funding, but does not capture every federal account that can be used for vaccine-related activities. This product does not address financing for vaccine administration (e.g., health insurance coverage) or globa